IRLAB: Missed top line readout with Pirepemat, detailed data indicate potential way forward - Redeye

Redeye reviews its valuation of IRLAB following the missed top-line readout with pirepemat in PD-fall. We think that there are actionable learnings from the deeper data analysis that motivate further development, most notably an analysis related to plasma concentration, but make some changes to our valuation as we expect a delay and less certain path compared to our previous assumptions.

Länk till analysen i sin helhet: https://www.redeye.se/research/1087980/irlab-missed-top-line-readout-with-pirepemat-detailed-data-indicate-potential-way-forward?utm_source=finwire&utm_medium=RSS